Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type2 diabetes: A meta-analysis
Blacklock CL., Hirst JA., Taylor KS., Stevens RJ., Roberts NW., Farmer AJ.
Aims Renin-angiotensin inhibitors in Type2 diabetes and microalbuminuria reduce renal and cardiovascular risk, but evidence supporting use of maximal tolerated dose is unclear. We aimed to determine the extent of renin-angiotensin inhibitor dose-dependent effects from randomized trials carried out in a clinical setting. Methods In a meta-analysis of randomized clinical trials, alternate doses of angiotensin receptor blockers or angiotensin converting enzyme inhibitors in patients with Type2 diabetes and microalbuminuria were compared. MEDLINE, EMBASE and the Cochrane Register of Controlled Trials were searched from January 2006 to August 2010. Trials prior to January 2006 were identified from a prior systematic review. Identified outcomes were albumin excretion rate, progression and regression of albuminuria and adverse events. Results Four trials including 1051 patients compared doses of angiotensin receptor blockers. No trials compared doses of angiotensin converting enzyme inhibitor. The percentage decline in albumin excretion rate from baseline was greater with higher doses (18% higher, 95%CI 8-28%), the regression to normoalbuminuria was greater (OR1.66, 95%CI 1.22-2.27), with less progression to macroalbuminuria (OR0.62, CI0.38-1.02). Adverse events were fewer with lower-dose angiotensin receptor blockers (OR1.32, 95%CI 0.90-1.92). Conclusions Higher-dose compared with lower-dose angiotensin receptor blockers in Type2 diabetes with microalbuminuria are associated with significantly reduced albumin excretion rate and increased regression to normoalbuminuria. Adverse events are more frequent, but not significantly so. There is potential for trials to determine clinical cardiovascular and renal outcomes at differing doses. Our findings support current recommendations to titrate renin-angiotensin inhibitors to maximum dose whilst considering risk of adverse side effects with higher doses. © 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.